Interleukin-17A is an important cytokine in the pathogenesis of psoriatic arthritis.
Secukinumab is a recombinant, high-affinity, fully human immunoglobulin G1κ monoclonal
antibody with a selective binding and neutralization of interleukin-17A. By providing an
alternative mechanism of action to current treatments, secukinumab has shown efficacy in
the key clinical domains of psoriatic arthritis. In the present paper, we discuss the role of
interleukin-17A as a clinically relevant target in the treatment of psoriatic arthritis, based on …